Organic Chemistry in Drug Discovery

Science

Volumn 303, Issue 5665, 2004, Pages 1810-1813

  MacCoss, Malcolm ^a   Baillie, Thomas A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICAL ENGINEERING; DATA REDUCTION; METABOLISM; TOXICITY;

DRUG DISCOVERY; ORGANIC CHEMISTRY;

DRUG PRODUCTS;

2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; ANTINEOPLASTIC AGENT; APREPITANT; CYTOCHROME P450; DRUG; GLYCOPROTEIN P; SUBSTANCE P;

PHARMACEUTICAL INDUSTRY;

DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG INDUSTRY; DRUG METABOLISM; HUMAN; LIPOPHILICITY; NAUSEA AND VOMITING; NONHUMAN; ORGANIC CHEMISTRY; PRIORITY JOURNAL; REVIEW; SOLUBILITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; CHEMISTRY, ORGANIC; CHEMISTRY, PHARMACEUTICAL; CHEMISTRY, PHYSICAL; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; DRUG TOXICITY; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY; STRUCTURE-ACTIVITY RELATIONSHIP; TECHNOLOGY, PHARMACEUTICAL;

EID: 1642294294     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1096800     Document Type: Review

References (17)

1. In this discussion, a "hit" is defined as a nonoptimized structure obtained from some screening process on a target protein. It is often a very weak binder and is likely to have a nonoptimized pharmacokinetic profile. A "Lead" is defined as a structure that has been derived from an early "hit" and, although still not fully optimized, has been shown to have some appropriate characteristics to be a precursor of a drug entity. Often a good lead will have shown some proof-of-concept activity in an in vivo pharmacological model, but will likely not have been fully optimized for pharmacokinetic properties or undesirable off-target activities.
2. C. A. Lipinski, F. Lombardo, B. W. Dominy, P. J. Feeney, Adv. Drug Delivery Rev. 23, 3 (1997).
3. In the discovery setting, the rule of five (2) predicts that poor absorption or permeation of drugs is more likely when a drug molecule possesses either (i) more than 5 hydrogen bond donors, (ii) 10 hydrogen bond acceptors, (iii) a molecular weight greater than 500, or (iv) a calculated logP greater than 5.
4. J. Uetrecht, Drug Discov. Today 8, 832 (2003).
5. D. C. Evans, A. P. Watt, D. A. Nicoll-Griffith, T. A. Baillie, Chem. Res. Toxicol. 17, 3 (2004).
6. See (17) for an excellent review of the cardiovascular effects manifested by QT interval prolongation and the evaluation of drug candidates for this parameter.
7. See the cover story in Drug Discov. Dev. 6, 30 (2003).
8. T. Koppal, Drug Discov. Dev. 6, 59 (2003).
9. A. DePalma, Drug Discov. Dev. 5, 50 (2002).
10. A. DePalma, Drug Discov. Dev. 6, 51 (2003).
11. M. McCoy, J.-F. Tremblay, Chem. Eng. News 81, 15 (2003).
12. A. M. Rouhi, Chem. Eng. News 81, 75 (2003).
13. T. Koppal, Drug Discov. Dev. 6, 22 (2003).
14. W. A. Korfmacher et al., Rapid Commun. Mass Spectrom. 15, 335 (2001).
15. J. J. Hale et al., J. Med. Chem. 41, 4607 (1998).
16. R. M. Snider et al., Science 251, 435 (1991).
17. R. Netzer, A. Ebneth, U. Bischoff, O. Pongs, Drug Discov. Today 6, 78 (2001).